Download Files:
PD-1/PD-L1-IN 3 (TFA)
$140 – $570
Products Details
Product Description
– PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases[1].
Web ID
– HY-103048A
Storage Temperature
– -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Shipping
– Blue Ice
Applications
– Cancer-programmed cell death
Molecular Formula
– C91H127F3N24O20S
References
– [1]MILLER, Michael Matthew, et al. Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions. WO2014151634A1.
Molecular Weight
– 1966.19
Compound Purity
– 99.34
SMILES
– OC(C(F)(F)F)=O.O=C(N([C@H](C(N([C@H](C(N[C@H](C(N[C@](CSCC(N[C@H](C(N([C@H](C(N[C@H](C(N1CCC[C@]1(C(N[C@]([H])(C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C2=O)CO)=O)CC3=CNC4=CC=CC=C34)=O)C)=O)CC(C)C)=O)CC5=CN=CN5)=O)[H])=O)CC(N)=O)=O)C)C)=O)CC6=CC=CC=C6)=O)([H])C(NCC(N)=O)=O)=O)CCCNC(N)=N)=O)CCCC)C)=O)CCCC)C)[C@](N2)([H])CC7=CNC8=CC=CC=C78
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– H2O : 50 mg/mL (ultrasonic)
Target
– PD-1/PD-L1
Pathway
– Immunology/Inflammation
Product type
– Peptides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
